TGA approves second COVID-19 vaccine for youngest children The Pfizer vaccine is now approved for use in children aged six months to five years, with Moderna already available to the age group.
Independent review into COVID vaccine procurement released Eight recommendations have been handed down, with the next two years identified as ‘critical’ to Australia’s recovery.
Vaccine rollout ‘relied on GP goodwill’: Study General practices involved in Australia’s COVID-19 vaccination program struggled to make ends meet, researchers say.
Vaccine rollout lessons put on hold An Audit Office report contains criticisms of planning and communication but offers few concrete suggestions for improvement.
Study flags knowledge gaps for shingles vaccine Research suggests that misconceptions remain about the shingles vaccine in use for the Government vaccination program for people over 70.
‘Breakthrough moment’: Monkeypox vaccine secured The Federal Government has procured 450,000 doses of the MPX vaccine, with the first shipments due to arrive shortly.
ATAGI approves Moderna vaccine for at-risk young children Parents are advised not to contact vaccine providers until bookings open, following decision to approve vaccination for the youngest cohort.
COVID vaccine safety data for children ‘extremely reassuring’ A new study tracking nearly 400,000 children aged 5–15 post-vaccination found adverse events were generally short-term and mild.
TGA green lights Nuvaxovid for 12–17-year-olds But while provisional approval has been granted, inclusion in the national program for this age group is yet to be confirmed.
Slight rise in adverse reactions for joint COVID and flu jabs A peer-reviewed article looking at the co-administration of COVID booster and flu vaccines in the US reports that most reactions tend to be mild.